Whether a p16-negative result is good or bad depends entirely on what type of tissue was tested. In most cancers, p16-negative is a concerning finding that signals more aggressive disease and lower survival rates. The major exception involves certain subtypes of melanoma, where the relationship flips. If you’re reading a pathology report that mentions p16 status, the cancer type and location are what determine what the result means for you.
What p16 Actually Does in Your Cells
The p16 protein acts as a brake on cell division. It blocks signals that tell cells to keep multiplying, forcing them into a permanent resting state called senescence. Young, healthy cells produce very little p16, but as cells age or encounter stress, p16 levels rise to prevent damaged cells from dividing uncontrollably. In this way, p16 functions as a natural tumor suppressor: it stops cells that might become cancerous from growing.
When pathologists test a tissue sample for p16, they stain it with a chemical marker and count how many cells light up. A sample is typically classified as p16-positive when 70% to 75% or more of tumor cells show staining, though some labs use a 50% cutoff. Anything below that threshold is reported as p16-negative.
In Throat Cancer, p16-Negative Is Bad News
The most common reason p16 status appears on a pathology report is oropharyngeal cancer, which includes cancers of the tonsils, base of the tongue, and back of the throat. Here, p16 serves as a proxy for whether the cancer was caused by HPV. Tumors driven by HPV tend to be p16-positive and respond dramatically better to treatment. P16-negative tumors in this location are typically caused by smoking, heavy alcohol use, or both, and they carry a far worse prognosis.
The survival gap is stark. In one study of oropharyngeal cancer patients treated with surgery, five-year overall survival was 91% for p16-positive disease compared to just 39.8% for p16-negative disease. Disease-specific survival (meaning deaths caused by the cancer itself, not other causes) was 95.2% versus 58.3%. These differences are large enough that the cancer staging system now uses entirely separate classification chapters for p16-positive and p16-negative throat cancers, reflecting the fact that they behave almost like two different diseases.
Because p16-positive oropharyngeal cancers respond so well, researchers are actively testing whether those patients can receive less aggressive treatment to reduce long-term side effects like difficulty swallowing and dry mouth. P16-negative patients are not candidates for this kind of treatment de-escalation. If anything, clinical trials for p16-negative tumors are exploring intensified treatment to try to improve their lower survival rates.
In Most Other Cancers, p16 Loss Is Also Unfavorable
Outside the throat, losing p16 expression generally means a tumor has disabled one of the body’s key defenses against uncontrolled growth. Research has consistently linked p16 loss to more aggressive tumors and worse outcomes across several cancer types, including pancreatic cancer, esophageal squamous cell carcinoma, certain leukemias, and lung cancer. In small lung adenocarcinomas, for instance, p16 inactivation has been associated with poor prognosis even when the tumors are caught early.
The pattern makes biological sense. When a cancer cell loses p16, it removes the brake on cell division, allowing faster and less regulated growth. Tumors that proliferate more rapidly tend to be harder to control with treatment and more likely to spread.
Melanoma Is an Exception
In mucosal melanoma, the relationship between p16 and outcomes runs in the opposite direction from what you might expect. A study of 59 patients with mucosal melanoma found that high p16 expression was associated with worse survival, not better. Patients with low p16 expression had a mean survival of over 36 months, compared to 22 months for those with high expression. Three-year survival was significantly worse in the high-p16 group.
This counterintuitive finding likely reflects the complex biology of melanoma, where p16 overexpression may signal a cellular stress response that correlates with more advanced disease rather than effective tumor suppression. For melanoma patients specifically, a p16-negative result may actually be the more favorable finding.
In Cervical Biopsies, p16 Helps Catch Hidden Problems
P16 testing also plays an important role in cervical cancer screening, though its purpose here is slightly different. When a cervical biopsy comes back looking normal under the microscope but an earlier Pap test was abnormal, pathologists sometimes stain the sample for p16 to check for precancerous changes that might have been missed on initial review.
In one study of 341 cervical biopsies initially read as negative, p16 staining detected missed abnormalities in about 3% of cases. More importantly, a positive p16 result on those biopsies predicted a 75% chance of finding high-grade precancerous changes on follow-up, compared to just 25% for p16-negative cases. So in this context, p16-negative is reassuring. It suggests the cervical tissue is less likely to harbor hidden precancerous lesions.
What Drives p16-Negative Cancers
In head and neck cancers, the main risk factors for p16-negative disease are smoking and alcohol. A large genetic analysis found that lifetime smoking exposure roughly tripled the risk of HPV-negative (and therefore typically p16-negative) head and neck cancer. Alcohol had an even stronger association, with higher weekly consumption linked to nearly an eightfold increase in risk for HPV-negative disease. Both smoking and alcohol contribute independently, meaning each one raises risk on its own, and together they compound the danger.
In other cancer types, p16 loss usually happens through genetic or chemical changes that silence the gene itself. The gene can be deleted, mutated, or switched off through a process called methylation, where chemical tags accumulate on the DNA and prevent the gene from producing its protein. These changes can be driven by carcinogen exposure, inherited genetic factors, or random errors during cell division.
How p16 Status Shapes Your Treatment
For oropharyngeal cancer, p16 status is one of the single most important factors guiding treatment decisions. P16-positive patients receive standard radiation doses (sometimes with chemotherapy), and ongoing clinical trials are testing whether reduced doses can maintain the same excellent outcomes while sparing patients from severe side effects. P16-negative patients receive full-intensity treatment, and some trials are testing whether adding extra therapies can close the survival gap.
The staging system itself reflects this divide. The American Joint Committee on Cancer uses completely separate staging criteria for p16-positive and p16-negative oropharyngeal tumors in its current guidelines. A tumor that would be classified as Stage I under the p16-positive system might be classified as a higher stage under the p16-negative system, because the expected behavior and outcomes are so different. Features like whether cancer has spread beyond a lymph node capsule factor into staging for p16-negative tumors but not for p16-positive ones.
Accurate testing matters. Some clinical trials have relied on p16 staining alone to classify tumors as HPV-related, but p16 can occasionally be positive for reasons unrelated to HPV. Patients whose tumors are p16-positive but not actually HPV-driven tend to have worse outcomes than true HPV-positive cases. Experts increasingly recommend confirming HPV status with a second test, especially when treatment de-escalation is being considered.